Pfizer completes acquisition of two GSK meningitis vaccines

Tools

In a move to ease antitrust concerns ahead of its multibillion-dollar asset swap with Novartis ($NVS), GlaxoSmithKline ($GSK) announced in June that it would sell two of its mature meningitis jabs to Pfizer ($PFE). The $130 million acquisition of Mencevax and Nimenrix has now closed. Both are marketed outside the U.S. and target the A, C, Y and W strains, but not the B strain. More

Comments